Ajanta Pharma Ltd. - Research Center
532331 AJANTPHARM Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sales | 3,971.12 | 3,411.27 | 3,140.64 | 2,718.59 | 2,196.42 |
| Operating profit | 1,119.43 | 650.98 | 890.89 | 916.91 | 532.78 |
| Interest | 6.80 | 5.23 | 9.12 | 6.90 | 9.10 |
| Gross profit | 1,229.11 | 826.80 | 1,021.50 | 1,013.58 | 707.88 |
| EPS (Rs) | 63.89 | 44.22 | 83.85 | 77.70 | 50.30 |
Annual
results in details
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Other income | 116.48 | 181.05 | 139.73 | 103.57 | 184.20 |
| Stock adjustment | -22.17 | -21.99 | -56.60 | -74.60 | 9.02 |
| Raw material | 939.43 | 878.36 | 773.04 | 704.09 | 556.22 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 834.16 | 720.41 | 585.87 | 498.11 | 437.82 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 1,100.27 | 1,183.51 | 947.44 | 674.08 | 660.58 |
| Provisions made | - | - | - | - | - |
| Depreciation | 132.16 | 126.95 | 120.96 | 111.49 | 91.29 |
| Taxation | 289.71 | 141.13 | 180.68 | 226.45 | 171.54 |
| Net profit / loss | 807.24 | 558.72 | 719.86 | 675.64 | 441.13 |
| Extra ordinary item | - | - | - | - | -3.92 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 25.27 | 25.27 | 17.17 | 17.39 | 17.54 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 28.19 | 19.08 | 28.37 | 33.73 | 24.26 |
| GPM (%) | 30.07 | 23.02 | 31.14 | 35.92 | 29.74 |
| NPM (%) | 19.75 | 15.55 | 21.94 | 23.94 | 18.53 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis